Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PTIXW
Upturn stock ratingUpturn stock rating

Protagenic Therapeutics Inc (PTIXW)

Upturn stock ratingUpturn stock rating
$0.06
Last Close (24-hour delay)
Profit since last BUY500%
upturn advisory
WEAK BUY
BUY since 21 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/13/2025: PTIXW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.06
high$

Analysis of Past Performance

Type Stock
Historic Profit 100%
Avg. Invested days 23
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/13/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.38
52 Weeks Range 0.00 - 0.24
Updated Date 05/24/2025
52 Weeks Range 0.00 - 0.24
Updated Date 05/24/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -189.6%
Return on Equity (TTM) -512.79%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 491613
Shares Outstanding -
Shares Floating 491613
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Protagenic Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Protagenic Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing novel peptide therapeutics. Further information regarding founding year and key milestones is not publicly available.

business area logo Core Business Areas

  • Peptide Therapeutics Development: Development of novel peptide therapeutics for neurological disorders and other diseases with unmet medical needs.

leadership logo Leadership and Structure

Details of Protagenic Therapeutics Inc's leadership team and organizational structure are not publicly available.

Top Products and Market Share

overview logo Key Offerings

  • PT00114: PT00114 is a lead drug candidate by Protagenic Therapeutics currently under development. Market share and revenue data are not publicly available. Competitors are other companies developing treatments for neurological disorders.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Innovation and strategic partnerships are crucial for success.

Positioning

Protagenic Therapeutics Inc. is positioned as an emerging biopharmaceutical company focused on peptide therapeutics. Competitive advantages would depend on the success and patentability of its drug candidates.

Total Addressable Market (TAM)

The TAM depends on the specific indications targeted by Protagenic's drug candidates. Information on this is not publicly available. Their positioning depends on the efficacy and market penetration of their pipeline drugs.

Upturn SWOT Analysis

Strengths

  • Novel peptide therapeutic approach
  • Targeting unmet medical needs

Weaknesses

  • Limited financial resources as a smaller biotech company
  • Dependence on successful clinical trials
  • No products currently on the market

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Positive clinical trial results
  • Expansion into new therapeutic areas

Threats

  • Failure in clinical trials
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

Competitive Landscape

A complete competitive landscape is difficult to ascertain due to limited public information on Protagenic's specific therapeutic targets and competitors.

Growth Trajectory and Initiatives

Historical Growth: There is no historical growth data available for Protagenic Therapeutics Inc.

Future Projections: Future growth projections are not available due to limited public information.

Recent Initiatives: Recent strategic initiatives data are not publicly available.

Summary

Protagenic Therapeutics Inc. is a small biopharmaceutical company focused on developing peptide therapeutics. It faces typical challenges of early-stage biotech companies, including funding, regulatory hurdles, and competition. Positive clinical trial results and strategic partnerships are crucial for its success. Financials, market share and leadership information are not publicly available.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company press releases
  • Industry reports

Disclaimers:

The information provided is based on limited publicly available data and should not be considered financial advice. This analysis is for informational purposes only. Market share data and other numerical values are estimates and should be verified with further research.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Protagenic Therapeutics Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2021-04-27
President, CEO & Director Mr. Barrett Evans
Sector Healthcare
Industry Biotechnology
Full time employees 1
Full time employees 1

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.